The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 5% in the afternoon. As of press release, it rose 4.31% to HK$37.74, with a turnover of HK$250 million.

According to the news, Insili Intelligence announced that the company recently released preliminary positive data from the first human phase I clinical trial of ISM6331 in the form of a quick oral report at the 2026 European Society of Medical Oncology (ESMO) annual meeting. ISM6331 is an oral pan-TEAD inhibitor under research designed with the help of the Chemistry42 generative AI platform.

As of the data cutoff date of August 14, 2026, among mesothelioma subjects whose efficacy can be assessed, the objective response rate (ORR) reached 40% in the 130 mg dose group once a day, and the disease control rate (DCR) at the time of initial tumor evaluation reached 68.2% within the 30-130 mg dose range.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.